Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: CLIC1 immunoexpression was evaluated in the vascular (CLIC1-V) and stromal (CLIC1-S) compartments of the RA and PsA skin biopsies of patients treated with methotrexate (MTX), leflunomid (LFN), corticotherapy (CT), or biological therapies. RESULTS: MTX significantly reduced CLIC1-S expression (p=0.016), whereas LFN decreased CLIC1-V (p<0.001). LFN therapy duration also correlated with CLIC1-V (p<0.001). CT decreased CLIC1-S expression (p=0.006). CLIC1-S expression persisted in skin biopsies despite of erythrocyte sedimentation rate (ESR, p=0.018) and C reactive protein (CRP, p=0.0026) normalisation. For PsA, CLIC1-S expression significantly related to MTX (p<0.022). Both CLIC1-S (p<0.001) and CLIC1-V (p=0.007) decreased by biological therapies in RA. CONCLUSION: CLIC1 expression is strongly influenced by the therapy used. Our data strongly support the extensive evaluation of CLIC1 in RA as a potential marker of inflammation and tool to predict therapy response.
|
Authors | Liliana Bordean, Monica Chis, Marius Raica, Ovidiu Simion Cotoi, Amalia Raluca Ceausu, Claudiu Avram, Anca Maria Cimpean |
Journal | In vivo (Athens, Greece)
(In Vivo)
2021 Sep-Oct
Vol. 35
Issue 5
Pg. 2559-2567
ISSN: 1791-7549 [Electronic] Greece |
PMID | 34410943
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- CLIC1 protein, human
- Chloride Channels
- Methotrexate
|
Topics |
- Arthritis, Psoriatic
(drug therapy, genetics)
- Arthritis, Rheumatoid
(drug therapy, genetics)
- Biopsy
- Chloride Channels
- Humans
- Methotrexate
- Skin
|